A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a late-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Our initial focus is on treating fibrosis by inhibiting integrin-mediated activation of TGF-β. We have applied our deep understanding of fibrosis biology, along with our medicinal chemistry and translational medicine expertise to develop a set of proprietary tools designed to discover and de-risk product candidates quickly and efficiently. Our wholly owned lead product candidate, bexotegrast, is an oral, small molecule, dual selective inhibitor of αvβ6 and αvβ1 integrins. We have recently discontinued BEACON-IPF trial, a global Phase 2b trial in patients with idiopathic pulmonary fibrosis (IPF). While an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo groups led to the discontinuation of the trial, early evidence of efficacy on the forced vital capacity (FVC) endpoint was also observed.
| Segment | 2022 | % of Total |
|---|---|---|
Integrin Research Target Program | $4M | 100% |
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | - | - | 42M |
| Net Income | -175M | -210M | -161M | -123M | -97M | -42M |
| EPS | $-2.86 | $-3.47 | $-2.75 | $-2.94 | $-2.71 | $-1.95 |
| Free Cash Flow | -159M | -159M | -117M | -96M | -77M | -39M |
| ROIC | -53.2% | -62.9% | -33.4% | -38.1% | -48.9% | - |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.15 | 0.10 | 0.02 | 0.03 | 0.00 | - |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -186M | -228M | -184M | -127M | -98M | -42M |
| Operating Margin | 0.0% | - | - | - | - | -99.6% |
| ROE | -87.6% | -54.1% | -34.1% | -39.4% | -48.9% | - |
| Shares Outstanding | 61M | 61M | 59M | 42M | 36M | 21M |
| Metric | 2019 | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 57M | 42M | N/A | N/A | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -1.2M | -42M | -98M | -127M | -184M | -228M | -186M |
| Op. Margin | -2.2% | -99.6% | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -6.9M | -42M | -97M | -123M | -161M | -210M | -175M |
| Net Margin | -12.0% | -99.3% | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | -0.8% | N/A | -48.9% | -38.1% | -33.4% | -62.9% | -53.2% |
| ROE | N/A | N/A | -48.9% | -39.4% | -34.1% | -54.1% | -87.6% |
| ROA | -5.8% | -14.1% | -44.0% | -35.2% | -31.5% | -46.3% | -63.4% |
| Cash Flow | |||||||
| Op. Cash Flow | -2.8M | -37M | -75M | -95M | -116M | -156M | -158M |
| Free Cash Flow | -3.7M | -39M | -77M | -96M | -117M | -159M | -159M |
| Owner Earnings | -5.7M | -42M | -87M | -119M | -163M | -195M | -198M |
| CapEx | 964K | 1.5M | 2.0M | 1.8M | 921K | 3.8M | 0 |
| Maint. CapEx | 1.1M | 1.3M | 1.5M | 1.8M | 1.8M | 2.1M | 2.1M |
| Growth CapEx | 0 | 222K | 418K | 0 | 0 | 1.7M | 0 |
| D&A | 1.1M | 1.3M | 1.5M | 1.8M | 1.8M | 2.1M | 2.1M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 1.8M | 3.9M | 10M | 23M | 44M | 38M | 38M |
| Debt Repayment | 0 | 0 | 0 | 150K | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | N/A | N/A | -201M | -321M | -484M | -326M | -211M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | N/A | 242M |
| Long-Term Debt | N/A | N/A | 0 | 9.9M | 10M | 30M | 30M |
| Debt/Equity | -0.12 | N/A | 0.00 | 0.03 | 0.02 | 0.10 | 0.15 |
| Interest Coverage | N/A | N/A | N/A | -160.8 | -145.3 | -75.5 | -75.5 |
| Equity | -76M | N/A | 199M | 313M | 474M | 304M | 200M |
| Total Assets | 119M | 296M | 221M | 351M | 512M | 397M | 277M |
| Total Liabilities | 9.1M | N/A | 22M | 37M | 39M | 93M | 76M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -76M | -118M | -215M | -338M | -500M | -710M | -710M |
| Working Capital | 104M | 279M | 193M | 316M | 477M | 329M | 329M |
| Current Assets | 112M | 291M | 209M | 340M | 506M | 362M | 362M |
| Current Liabilities | 8.2M | 12M | 17M | 24M | 29M | 33M | 33M |
| Per Share Data | |||||||
| EPS | -4.22 | -1.95 | -2.71 | -2.94 | -2.75 | -3.47 | -2.86 |
| Owner EPS | -0.16 | -1.99 | -2.44 | -2.84 | -2.77 | -3.22 | -3.22 |
| Book Value | -2.13 | N/A | 5.55 | 7.47 | 8.07 | 5.02 | 3.26 |
| Cash Flow/Share | -0.08 | -1.75 | -2.10 | -2.26 | -1.98 | -2.57 | -2.82 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 35.7M | 21.3M | 35.9M | 41.9M | 58.7M | 60.6M | 61.4M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | -0.5 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 2.5 | 2.5 | 2.4 | 2.7 | 0.4 |
| Price/Sales | N/A | 12.9 | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | N/A | -7.2% | -15.6% | -12.4% | -10.5% | -19.4% | -198.8% |
| Market Cap | N/A | 536M | 495M | 776M | 1.1B | 822M | 80M |
| Avg. Price | N/A | 25.27 | 25.19 | 14.18 | 21.12 | 13.88 | 1.30 |
| Year-End Price | N/A | 25.16 | 13.80 | 18.50 | 19.11 | 13.56 | 1.30 |
PLIANT THERAPEUTICS, INC. passes 0 of 9 quality checks, indicating weak fundamentals.
PLIANT THERAPEUTICS, INC. (PLRX) has a 5-year average return on invested capital (ROIC) of -45.8%. This is below average and may indicate limited pricing power.
PLIANT THERAPEUTICS, INC. (PLRX) has a market capitalization of $80M. It is classified as a small-cap stock.
PLIANT THERAPEUTICS, INC. (PLRX) does not currently pay a regular dividend.
PLIANT THERAPEUTICS, INC. (PLRX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
PLIANT THERAPEUTICS, INC. (PLRX) generated $-159 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
PLIANT THERAPEUTICS, INC. (PLRX) has a debt-to-equity ratio of 0.10. This indicates a conservatively financed balance sheet.
PLIANT THERAPEUTICS, INC. (PLRX) reported earnings per share (EPS) of $-3.47 in its most recent fiscal year.
PLIANT THERAPEUTICS, INC. (PLRX) has a return on equity (ROE) of -54.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 6 years of financial data for PLIANT THERAPEUTICS, INC. (PLRX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PLIANT THERAPEUTICS, INC. (PLRX) has a book value per share of $5.02, based on its most recent annual SEC filing.